大洋生物(003017) - 2025 Q3 - 季度业绩预告

I. Expected Performance for the Current Period The company forecasts a year-on-year increase in net profit attributable to shareholders and net profit after non-recurring items for Q1-Q3 2025, with net profit expected between 74 million and 90 million yuan, a growth of 44.35% to 75.56% 1. Performance Forecast Period This section specifies the period covered by the performance forecast - The performance forecast covers the period from January 1, 2025, to September 30, 2025[3] 2. Performance Forecast Details This section details the company's projected net profit and related financial metrics for the forecast period - The company expects positive net profit for Q1-Q3 2025, showing a year-on-year increase compared to the same period last year[4] Key Financial Indicators for Q1-Q3 2025 Performance Forecast (Unit: 10,000 yuan) | Item | Estimated Range for Current Period (10,000 yuan) | Same Period Last Year (10,000 yuan) | Year-on-Year Growth | | :--- | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | 7,400 — 9,000 | 5,126.58 | 44.35% — 75.56% | | Net Profit After Non-Recurring Items | 6,700 — 8,200 | 4,818.72 | 39.04% — 70.17% | | Basic Earnings Per Share (yuan/share) | 0.91 — 1.11 | 0.62 | - | II. Communication with Accounting Firm The financial data in this performance forecast has not been pre-audited by an accounting firm - The financial data in this performance forecast has not been pre-audited by Zhonghui Certified Public Accountants (Special General Partnership)[6] III. Explanation of Performance Changes Net profit growth is primarily due to increased market demand, driving up sales and prices of key products like potassium carbonate and veterinary APIs, thereby improving gross margin - The primary reason for the year-on-year increase in net profit is increased market demand, which drove up both sales volume and prices of key products like potassium carbonate and veterinary APIs[7] - The rise in sales volume and prices of main products led to an increase in the company's gross margin[7] IV. Risk Warning The company advises investors that this performance forecast is a preliminary estimate, with final financial data subject to the officially disclosed Q3 2025 report, and highlights investment risks - This performance forecast represents the preliminary estimation by the company's finance department[8] - The definitive financial data will be based on the company's officially disclosed Q3 2025 report[8] - The company advises investors to exercise caution in their decisions and be aware of investment risks[8]